China’s Mindray Refutes Merit Of Report That Sent Stock Plummeting
This article was originally published in The Gray Sheet
Executive Summary
Mindray stock recovers from freefall after allegations that China’s leading medical device company overstated its earnings and engaged in fraudulent accounting practices.
You may also be interested in...
Mindray Doubles Patient Monitor Biz, Builds U.S. Presence With Acquisition
China-based Mindray Medical will supply components for Datascope's patient monitoring business unit after acquiring the subsidiary for $202 million in a deal announced March 11
Upgraded Paige Suite Gains CE-IVD and UKCA Marks
Paige’s AI has obtained CE-IVD and UKCA marks, allowing the launch of a breakthrough product that can spot biomarkers from images.
Sanofi's Sarclisa Scores In Myeloma But Is Still In Darzalex’s Shadow
The French company believes it has the best-in-class CD38 antibody with new PFS data, but Johnson & Johnson and Genmab’s Darzalex looks set to retain its advantage in multiple myeloma.